Rezera postpones a planned $200M IPO shortly before expected debut

Rezera, a biotech developing drugs for cardio and inflammatory diseases, has delayed its IPO that was scheduled for Friday, a company spokesperson confirmed to Endpoints News. The spokesperson cited “current market conditions” as the reason ...